Bicycle Therapeutics plc (NASDAQ:BCYC) Stock Position Lowered by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC lessened its position in Bicycle Therapeutics plc (NASDAQ:BCYC) by 29.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,707 shares of the company’s stock after selling 2,767 shares during the period. Exchange Traded Concepts LLC’s holdings in Bicycle Therapeutics were worth $152,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of BCYC. GAMMA Investing LLC raised its position in shares of Bicycle Therapeutics by 105.1% during the third quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock worth $46,000 after purchasing an additional 1,038 shares during the period. PNC Financial Services Group Inc. acquired a new stake in shares of Bicycle Therapeutics during the fourth quarter worth $137,000. XTX Topco Ltd acquired a new stake in shares of Bicycle Therapeutics during the second quarter worth $206,000. PDS Planning Inc acquired a new stake in shares of Bicycle Therapeutics during the first quarter worth $210,000. Finally, Natixis Advisors LLC acquired a new stake in shares of Bicycle Therapeutics during the second quarter worth $261,000. Institutional investors own 86.15% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 target price on shares of Bicycle Therapeutics in a research report on Monday, September 16th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicycle Therapeutics in a research report on Monday, September 9th. B. Riley downgraded Bicycle Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the company from $33.00 to $28.00 in a report on Wednesday, August 7th. Oppenheimer reiterated an “outperform” rating and set a $48.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, August 7th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $38.00 price target on shares of Bicycle Therapeutics in a report on Monday, September 16th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Bicycle Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $44.56.

Insider Buying and Selling at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,212 shares of the business’s stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total value of $71,499.12. Following the transaction, the chief executive officer now owns 380,864 shares in the company, valued at $8,478,032.64. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold 4,584 shares of company stock worth $102,040 over the last 90 days. 8.50% of the stock is currently owned by corporate insiders.

Bicycle Therapeutics Stock Performance

Shares of NASDAQ BCYC opened at $26.70 on Tuesday. The business’s 50-day moving average price is $23.83 and its two-hundred day moving average price is $23.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.77 and a quick ratio of 14.77. Bicycle Therapeutics plc has a one year low of $12.54 and a one year high of $28.67. The company has a market capitalization of $1.14 billion, a P/E ratio of -6.00 and a beta of 0.89.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Tuesday, August 6th. The company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.33. Bicycle Therapeutics had a negative return on equity of 32.80% and a negative net margin of 417.88%. The firm had revenue of $9.36 million for the quarter, compared to the consensus estimate of $6.13 million. The business’s revenue for the quarter was down 17.9% compared to the same quarter last year. Analysts anticipate that Bicycle Therapeutics plc will post -3.17 earnings per share for the current fiscal year.

Bicycle Therapeutics Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.